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Abstract
Esophageal squamous cell carcinoma (ESCC) is an aggressive tumor, and it is ur-
gently needed to develop novel therapeutic strategies including immunotherapy. In 
this study, we investigated the upregulation of the programmed death ligand 1 (PD- 
L1) due to epithelial- mesenchymal transition (EMT) in ESCC using an in vitro treat-
ment system with the EMT inducer, glycogen synthase kinase (GSK)- 3 inhibitor, 
and we also analyzed the correlation of EMT and PD- L1 expression in the clinical 
tumor samples of both tissue microarray (TMA) samples (n = 177) and whole tissue 
samples (n = 21). As a result, the inhibition of GSK- 3β induces EMT phenotype 
with upregulated vimentin and downregulated E- cadherin as well as increased Snail 
and Zinc finger E box- binding homeobox (ZEB)- 1 gene expression. Simultaneously, 
we showed that EMT- converted ESCC indicated the upregulation of PD- L1 at both 
protein (total and surface) and mRNA levels. Of importance, we showed that EMT- 
converted tumor cells have a capability to induce T- cell apoptosis to a greater extent 
in comparison to original epithelial type tumor cells. Furthermore, the immunohisto-
chemical stains of ESCC showed that PD- L1 expression on tumor cells was posi-
tively correlated with EMT status in TMA samples (P = .0004) and whole tissue 
samples (P = .0029). In conclusion, our in vitro and in vivo study clearly demon-
strated that PD- L1 expression was upregulated in mesenchymal type tumors of 
ESCC. These findings provide a strong rationale for the clinical use of anti- PD- 1/
anti- PD- L1 monoclonal antibodies for advanced ESCC patients.
K E Y W O R D S
epithelial-mesenchymal transition, esophageal squamous cell carcinoma, glycogen synthase kinase-3β, 
immunotherapy, programmed death ligand 1
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1 |  INTRODUCTION
Esophageal cancer affects more than 450 000 people, and 
the incidence is increasing worldwide now.1 Globally, 
esophageal cancer is the sixth most common malignancy in 
men and the sixth most common cause of death from can-
cer,2 and the majority of the cases in Asian countries are 
esophageal squamous cell carcinoma (ESCC). The over-
all survival of the patients with advanced ESCC remains 
still poor despite the multidisciplinary treatment includ-
ing surgery, chemotherapy, radiotherapy, and molecular- 
targeted drug treatment.3-7 Therefore, it is urgently needed 
to develop novel therapeutic strategies for advanced 
ESCC.
Immunotherapy has recently become an important part 
of cancer treatment.8,9 The most successful immunother-
apy in solid human cancers is the administration of im-
mune checkpoint inhibitors, including antibodies against 
cytotoxic T lymphocyte- associated antigen 4 (CTLA4), 
programmed death 1 (PD- 1), and programmed death li-
gand 1 (PD- L1). The PD- L1 expressed on tumor cells 
binds to PD- 1 on tumor infiltrating lymphocytes (TILs) 
in tumor microenvironments, allowing tumor cells to es-
cape from immune attack with TILs and leading TILs to 
apoptosis.10-12 As there are several clinical trials of the 
anti- PD- 1 monoclonal antibody (mAb) induced significant 
clinical responses among the several types of the refrac-
tory tumors,13-17 the inhibition of PD- 1/PD- L1 interaction 
by therapeutic mAb would be a new promising strategy for 
ESCC.
PD- L1 expression within tumor microenvironment is 
regulated by the innate immune resistance which includes 
oncogenic pathways on tumor cells and acquired immune 
resistance such as IFN- γ, signaling pathways, and transcrip-
tional factors.18-23 Furthermore, it has recently been reported 
that microRNA- 200/Zinc finger E box- binding homeobox 
(ZEB)- 1 axis controls both epithelial- mesenchymal tran-
sition (EMT) and PD- L1 expression in tumor cells.24 EMT 
is the process which allows tumor cells to enter the blood-
streams and lymphatics by changing their phenotype into mo-
bile mesenchymal form to undergo distant metastasis.25 The 
tumor cells undergoing EMT also express PD- L1, which is 
one of the essential factors of immune evasion, on the way to 
the distant metastatic sites.
In this study, therefore, ESCC cell lines treated with 
glycogen synthase kinase (GSK)- 3 inhibitor were used to 
determine whether EMT conversion could induce upregula-
tion of PD- L1 along with increased T- cell apoptosis. Also, 
we evaluated the correlation of EMT status with PD- L1 
expression in ESCC samples, using 2 independent cohorts 
of tissue microarray (TMA) and whole tissues sections ob-
tained from a total of 198 patients with ESCC who under-
went surgery.
2 |  MATERIALS AND METHODS
2.1 | Tumor cell lines
ESCC cell lines, KYSE30 and KYSE110, were purchased 
from the Japanese Collection of Research Bioresources Cell 
Bank (Osaka, Japan). SW480 and HCT116, Colon cancer 
cell lines, were purchased from the American Type Culture 
Collection (Manassas, VA, USA) and RIKEN Bio Resource 
Center (Ibaraki, Japan), respectively. All cell lines were cul-
tured in RPMI- 1640 (Sigma- Aldrich, St. Louis, MO, USA) 
with 10% fetal bovine serum (Biological Industries Kibbutz 
Beit Haemek and, Haifa, Israel) and 1% antibiotic- antimycotic 
(Thermo Fisher Scientific, Waltham, MA, USA).
2.2 | EMT induction
EMT induction was performed using GSK- 3 inhibitor, SB- 
415286 (S3567_SIGMA; Sigma- Aldrich) which also inhib-
its the kinase activity of GSK- 3β,26 dissolved with DMSO, 
and DMSO was used as a vehicle control. The inhibition of 
the GSK- 3β induces the upregulation of Snail gene which 
leads tumor cells to EMT and SB- 415286 promotes the Snail 
gene transcription.27,28 Tumor cells were grown to subconflu-
ency and treated with 5 or 50 μmol/L of SB- 415286 for 12- 
72 hours. After 48 hours incubation with SB- 415286, tumor 
cells were morphologically checked by microscope and were 
analyzed by Western blot and flow cytometry or were used 
for coculture experiments. For qRT- PCR, tumor cells were 
incubated with SB- 415286 for 12- 72 hours.
2.3 | Western blotting
The cells were collected using simple scraping method, 
and the pellets were lysed in RIPA buffer (Thermo Fisher 
Scientific) with phenylmethanesulfonyl fluoride (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), protease inhibitor 
cocktail (Santa Cruz Biotechnology) and sodium orthovana-
date (Santa Cruz Biotechnology). The protein concentration 
of the lysates was measured with Bradford Reagent (Bio- 
Rad, Hercules, CA, USA). Electrophoresis was performed 
using X cell sure lock port with 4%- 20% Tris- glycerin gel 
(Invitrogen, Carlsbad, CA, USA), and the protein samples 
were transferred to Polyvinylidene difluoride (PVDF) mem-
brane using iBlot 2 (Invitrogen). PVDF membranes were 
blocked with 1% Tris- buffered saline containing Tween 
(Cell Signaling Technology, Danvers, MA, USA) with 2% 
nonfat dry milk. The PVDF membranes were incubated with 
β- actin mouse antibody (1:2000; Santa Cruz Biotechnology) 
in TBST for 1 hour and then incubated with the HRP- linked 
anti- mouse antibody (1:2500; Santa Cruz Biotechnology) in 
TBST for 1 hour. To detect PD- L1, the PVDF membranes 
were incubated with XP(R) Rabbit, PD- L1 antibody (clone 
E1L3N; Cell Signaling Technology) at 1:1000 dilution in 
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TBST overnight at 4°C. After incubating with appropriate 
secondary antibodies, the protein signals were visualized 
with SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Fischer) for 5 minutes according to manufacturer’s 
protocol, and images were captured by LAS- 4000 lumines-
cent image analyzer mini (Fujifilm, Tokyo, Japan).
Detecting how GSK- 3 inhibitor, SB- 415286, downregu-
lates GSK- 3β subunit, the same method of electrophoresis 
and membrane transfer was carried out with the protein ly-
sate of KYSE 30 or KYSE110 cell line. Then, the membrane 
was blocked with 5% BSA in TBST overnight at 4°C. The 
membrane was later incubated with the primary anti- GSK- 3 
(alpha + beta) (phospho Y216 + Y279) antibody (Abcam, 
Cambridge, UK) for 2 hours in the room temperature. The 
secondary antibody and the visualization of protein signals 
were same as above.
To detect proteins of EMT status, tumor cell lines were de-
tached using enzyme- free dissociation buffer and then lysed 
with cell lysis cocktail containing cell lysis buffer (Sigma- 
Aldrich), protease inhibitor (Sigma- Aldrich), and phospha-
tase inhibitor (Sigma- Aldrich). An equal amount of protein 
samples was loaded on NuPAGE Novex 4%- 12% Bis- Tris pre-
cast gels (Thermo Fisher Scientific) and transferred to PVDF 
membranes using the iBlot Dry Blotting System (Thermo 
Fisher Scientific). PVDF membranes were blocked with ei-
ther 5% nonfat milk for 2 hours at room temperature and then 
incubated with primary antibodies overnight at 4°C. PVDF 
membranes were incubated with anti- rabbit or anti- mouse 
HRP- linked antibodies (Cell Signaling Technology). Blots 
were visualized by SignalFire™ ECL Reagent (Cell Signaling 
Technology), and images were captured by ImageQuant 
LAS500 (GE Healthcare Life Science, Princeton, NJ, USA). 
The following antibodies were used as primary antibodies: 
E- cadherin (1:5000; Santa Cruz Biotechnology), vimentin 
(1:5000; Santa Cruz Biotechnology), Snail (1:100; Santa 
Cruz Biotechnology), and Actin (1:5000; Cell Signaling 
Technology).
2.4 | Flow cytometry
Following manufacturer’s flow cytometry preparation proto-
col, in brief, cells were stained with antibodies for 15 minutes 
at room temperature in the dark. After incubation, stained 
cells were analyzed using flow cytometry. The follow-
ing antibodies were used for staining: PE- conjugated anti- 
human CD274 (B7- H1; PD- L1) (eBioscience, San Diego, 
CA, USA), APC- H7 conjugated anti- human CD3 (Becton 
Dickinson Bioscience, San Jose, CA, USA), PE- conjugated 
Annexin V (Becton Dickinson Bioscience), PerCP- Cy5.5 
conjugated 7- Aminoactinomycin D (7- AAD) (Becton 
Dickinson Bioscience), and APC- conjugated E- cadherin 
(Biolegend, San Diego, CA, USA). Isotype- matched immu-
noglobulin served as a negative control, and staining intensity 
was measured by FACSCanto II flow cytometer (Becton 
Dickinson Bioscience), and data were analyzed using Flowjo 
Software (Flowjo, Ashland, OR, USA).
2.5 | qRT- PCR analysis
TRIzol reagent (Invitrogen) was used to collect the speci-
men, and RNA isolation was performed according to stand-
ard protocol. cDNA was synthesized using SuperScript III 
First- Strand Synthesis System for RT- PCR (Invitrogen) on 
Veriti 96- well thermal cycler (Applied Biosystems, Foster 
City, CA, USA). The PCR analysis was performed using 
TaqMan Gene Expression Assays (Applied Biosystems) 
with CDH1(E- cadherin), Snail, CD274 (PD- L1), and 
ZEB- 1 according to the protocol from the manufacturer. 
GAPDH was used as the endogenous control. The plate 
was analyzed with 7500 Real- time PCR system (Applied 
Biosystems). The  relative expression levels were normalized 
to GAPDH and calculated by the 2−ΔΔCt method. The fol-
lowing probes were used for PCR: GAPDH (hs99999905_
m1), CDH1(E-cadherin) (hs01023894_m1), SNAI1(Snail) 
(hs00195591_m1), CD274(PDL1) (hs01125301_m1), and 
ZEB1 (hs00232783) (all from Applied Biosystems).
2.6 | Coculture experiment
Peripheral blood mononuclear cells (PBMCs) were isolated 
from the fresh blood of healthy donor by density gradient 
centrifugation using Ficoll- Paque (GE Healthcare, Uppsala, 
Sweden) The PBMCs were cultured in AIM- V medium 
(Thermo Fisher Scientific) with 200 IU/mL of human IL- 2 
(Sigma- Aldrich) for 7 days. Fresh medium and IL- 2 were 
replenished every 3 days. After 7 days of culture, the IL- 2 
activated lymphocytes including T cells, expressing PD- 1 
(data not shown),29 were used for coculture experiments. The 
IL- 2 activated lymphocytes were cocultured with the GSK- 3 
inhibitor or DMSO- treated tumor cells at 1:1 ratio in 24- well 
plates for 48 hours. After 48- hour incubation, the proportion 
of apoptotic CD3- positive cells, T cells, were analyzed with 
Annexin V and 7- AAD using flow cytometry. The 3 inde-
pendent coculture experiments were performed. This study 
was also approved by the Institutional Review Board of 
Fukushima Medical University.
2.7 | Patient’s samples
One hundred and seventy- seven TMA samples (3 cores 
each from 177 tumors) of patients with ESCC, who under-
went esophagectomy between January 2000 and December 
2011, were provided from Department of Thoracic Surgery, 
Akita University Graduate School of Medicine.30 We also 
obtained 21 formalin- fixed paraffin embedded (FFPE) whole 
tissue samples of ESCC, which were surgically resected at 
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Department of Gastrointestinal Tract Surgery, Fukushima 
Medical University between April 2003 and January 2016. 
The study was conducted in accordance with the Declaration 
of Helsinki and was approved by the ethics committee of 
the Akita University School of Medicine and Fukushima 
Medical University School of Medicine.
2.8 | Immunohistochemistry (IHC)
Both TMA and whole tissue samples of ESCC (4 μm thick) 
were deparaffinized in xylene and rehydrated through a 
graded ethanol series. Endogenous peroxidase activity was 
inactivated by incubation in 0.3% hydrogen peroxide in 
methanol. For E- cadherin staining, antigens on the samples 
were retrieved using autoclaving for 5 minutes in 10 mmol/L 
citrate buffer solution (105°C, pH 6.0), and the samples were 
incubated with the primary mouse monoclonal antibody 
for E- cadherin (1:200, NCH- 38, Dako) at 4°C overnight 
and detected a horseradish peroxidase (HRP)- coupled anti- 
mouse polymer (Envision+System- HRP, Dako, Belgium) 
followed by incubation with diaminobenzidine (DAB, 
Dojindo, Maryland). For vimentin staining, the heat- induced 
epitope retrieval (HIER) steps were not necessary; therefore, 
the samples were directly incubated with the primary rab-
bit polyclonal antibody for vimentin (SP20, 1:400; Nichirei 
Bioscience, Tokyo, Japan) and detected by a HRP- coupled 
anti- rabbit polymer (Envision+System- HRP, Dako) fol-
lowed by incubation with DAB (Dako). For PD- L1 stain-
ing, antigen retrieval was performed using autoclaving for 
10 minutes in TE buffer (120°C, pH 9.0) and incubated with 
F I G U R E  1  Treatment with GSK- 3 inhibitor induces epithelial- mesenchymal transition in KYSE30, esophageal squamous cell carcinoma cell 
line. (A) GSK- 3 inhibitor, SB- 415286, reduces the expression of the GSK- 3β protein in a dose- dependent manner (Control, 5 μmol/L, 50 μmol/L). 
(B) Western blot analysis showed the downregulation of E- cadherin, epithelial marker, and the upregulation of vimentin, mesenchymal marker, after 
exposure to 50 μmol/L of GSK- 3 inhibitor. (C) QT- PCR analysis showed the significant downregulation of E- cadherin gene expression, epithelial 
marker, and the significant upregulation of Snail as well as ZEB- 1 gene expression, mesenchymal marker, at different time points (24 and 48 h) 
after exposure to the 50 μmol/L of GSK- 3 inhibitor. DMSO was used for untreated control. Three independent experiments were performed. (D) 
Microscopic images showed the morphological changes after treatment with a GSK- 3 inhibitor (Control, 5 μmol/L, 50 μmol/L) for 48 h. Spindle- 
shaped cells with loss of cell to cell adhesion were seen in 50 μmol/L treatment. *<.05, **<.01
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the primary rabbit polyclonal antibody for PD- L1 (E1L3N, 
1:400; Cell Signaling). The detection steps for PD- L1 were 
same as vimentin.
TMA samples (triplicate cores from 1 tumor) were evalu-
ated with immunoreactivity score (IRS) as follows: Staining 
intensity score where, weak staining = 1, moderate stain-
ing = 2, strong staining = 3, and staining percentage score 
where <5% of staining area = 0, 5%- 25% of staining = 1, 
26%- 50% of staining = 2, 51%- 75% of staining = 3, and 
>75% of staining = 4. Multiplication of these 2 scores (in-
tensity score and percentage score) resulted in the IRS score 
which varies from 0 to 12. From IRS score, E- Cadherin ≥5 
is considered as positive, and vimentin ≥4 is considered as 
positive.31 PD- L1 is considered as positive if ≥5% of area is 
positive with weak, moderate, and strong staining intensity; 
therefore, IRS score 0 is considered as negative, and the rest 
are considered as positive.32
Evaluating of FFPE tissue samples was done using 
H- score which was calculated by following formula: 1 × (per-
centage of cells showing weak staining) + 2 × (percentage of 
cells showing moderate staining) + 3 × (percentage of cells 
showing strong staining). Definition of EMT phenotype is 
as low E- cadherin expression with H- score ≤200 and high 
vimentin expression with H- score ≥30. For PD- L1, IHC 
was evaluated from intensity and proportion of membranous 
staining with or without cytoplasmic staining, and it was 
scored as 0 = <5% of tumor cells, 1 = weak stain in ≥5% 
of tumor cells, 2 = moderate stain in ≥5% of tumor cells, 
3 = strong stain in ≥5% of tumor cells. Therefore, scores 1, 
2, and 3 were considered as PD- L1 positive.33 The evaluation 
F I G U R E  2  PD- L1 was upregulated in total protein, surface expression, and gene expression in tumor cell lines treated with the GSK- 3 
inhibitor. (A) After exposure to GSK- 3 inhibitor for 48 h, Western blot analysis showed the upregulation of total PD- L1 protein in a dose- dependent 
manner in esophageal squamous cell carcinoma cell lines, KYSE30 and KYSE110, and colon cancer cell lines, HCT116 and SW480. (B) Flow 
cytometry analysis showed the upregulation of surface expression of PD- L1 after GSK- 3 inhibitor treatment (Control, 5 μmol/L, 50 μmol/L) for 
48 h in tumor cell lines. (C) The significant upregulation of PD- L1 gene expression in tumor cell lines treated with GSK- 3 inhibitor at 24 h. DMSO 
was used for untreated control. *<.05, **<.01
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was performed by SK and AT in separately without prior 
knowledge of clinicopathological data.
2.9 | Statistics
Statistical differences between 2 groups were evaluated 
by Fischer’s exact test using GraphPad Prism 6 software 
(GraphPad Software Incorporation, CA).
The Student t test was used to show the significant dif-
ferences between 2 pair groups or independent groups with 
the same variables. The standard mean error (SEM) was also 
calculated and used as the error bar.
3 |  RESULTS
3.1 | EMT induced by GSK- 3 inhibitor
We induced EMT in ESCC cell lines, KYSE30 and 
KYSE110, and colon cancer cell lines, HCT116 and SW480, 
using GSK- 3 inhibitor, SB- 415286. As a representative data, 
the results of KYSE30 were shown in Figure 1. At first, 
we proved that SB- 415286 reduced the expression of the 
GSK- 3β protein in a dose- dependent manner in KYSE30 
cell line. (Figure 1A) and KYSE110 cell line (Figure S1a). 
Tumor cell lines treated with GSK- 3 inhibitor showed the 
significant downregulation of E- cadherin and the significant 
upregulation of mesenchymal genes vimentin and Snail 
in Western blot and/or PCR analysis (Figure 1B,C and 
Figure S1b and S2) and the morphological changes including 
spindle- like morphology and mesenchymal- like phenotype 
with loss of cell to cell adhesion (Figure 1D and Figure S1c), 
these results showed that GSK- 3 inhibitor was inducing the 
EMT in these tumor cell lines.
3.2 | Upregulation of total as well as surface 
PD- L1 expression after EMT
After EMT conversion using SB- 415286, we examined the 
PD- L1 expression in KYSE30, KYSE110, HCT116, and 
SW480. Both total amount of PD- L1 protein and surface ex-
pression of PD- L1 in EMT- converted tumor cells were in-
creased in a dose- dependent manner (Figure 2A,B). These 
results suggested that total amount of PD- L1 protein as well 
as the surface expression of PD- L1 was significantly in-
creased in EMT- converted tumor cells regardless of tumor 
type. PCR analysis also showed an increment of both gene 
expressions of PD- L1 (Figure 2c, Figure S3) and ZEB- 1 in 
GSK- 3 inhibitor- treated group (Figure 1c, Figure S2). To 
show the relationship between EMT conversion and PD- L1 
expression, we used the double staining of E- cadherin and 
PD- L1 on EMT- converted tumor cells and the control. The 
EMT- converted tumor cells showed the upregulation of 
F I G U R E  3  The apoptosis of IL- 
2- activated T cells was induced by the 
coculture with GSK- 3 inhibitor- treated 
tumor cells. (A) The proportion of apoptotic 
cells was determined using Annexin V and 
7- AAD staining, and the representative 
figure of 3 independent experiments 
was shown. The proportion of apoptotic 
IL- 2- activated T cells without tumor cells 
was 11.1%. The proportion of apoptotic 
IL- 2- activated T cells was increased in the 
coculture with GSK- 3 inhibitor- treated 
KYSE30 (59.7%), compared to the coculture 
with untreated KYSE30 (36.4%) DMSO 
was used for the untreated control. (B) The 
summery of 3 independent experiments 
showed the significant difference between 
control and GSK- 3 inhibitor- treated 
groups, of KYSE30 (P = .028) and SW480 
(P = .041) cell lines, respectively. A paired 
Student’s t test was used for the statistical 
analysis. *<.05
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PD- L1 and the downregulation of E- cadherin at the same 
time (Figure S5).
3.3 | EMT- converted tumor cells induced 
immune suppression
As the EMT conversion using SB- 415286 upregulated the 
surface expression of PD- L1 on tumor cells, we next per-
formed coculture experiment using EMT- converted tumor 
cells and IL- 2- activated T cells expressing PD- 1 to examine 
whether an increment of surface PD- L1 expression on tumor 
cells functionally induces T- cell apoptosis. The proportion of 
apoptotic T cells after coculture with EMT- converted tumor 
cells were analyzed using flow cytometry. To analyze the 
proportion of apoptotic IL- 2- activated T cells, CD3- positive 
cells were gated out of all cells from culture- well, and the 
proportion of Annexin V and 7- AAD- positive cells were 
measured in gated population (Figure 3A and Figure S4). 
The results from 3 independent experiments showed the sig-
nificant difference between GSK- 3 inhibitor- treated and non-
treated groups in both KYSE30 cell line and SW480 cell line 
with P = .028 and P = .041, respectively (Figure 3B). This 
result indicated that the surface expression of PD- L1 on the 
EMT- converted cancer cells functionally led T cells express-
ing PD- 1 to apoptosis.
3.4 | The PD- L1 expression on tumor cells 
was correlated with EMT status in ESCC
In order to examine the correlation between EMT status and 
the PD- L1 expression on tumor cells, IHC for E- cadherin, 
vimentin, and PD- L1 was performed in TMA and FFPE 
tissue samples of ESCC. Clinicopathologic features of the 
patients were summarized in the Table 1, and the representa-
tive immunohistochemical stains were shown in Figure 4. 
In both TMA and FFPE tissue samples, the cases with 
E- cadherin negative and vimentin positive were considered 
as EMT (+), while E- cadherin positive and vimentin nega-
tive were considered as EMT (−), and both positive cases 
and both negative cases were considered as uncertain. As 
a result, the proportion of PD- L1- positive cases on tumor 
cells was positively correlated with EMT (+) status in TMA 
samples (P = .0004) (Figure 4A and 5A) and in FFPE tis-
sue samples (P = .0029) (Figure 4B and 5B). Collectively, 
the IHC study confirmed the observation that EMT of tumor 
cells strongly associated with upregulation of PD- L1 expres-
sion in ESCC.
4 |  DISCUSSION
The treatment against metastatic ESCC is still challeng-
ing, and immunotherapy with anti- PD- 1 mAb is becoming 
a promising novel strategy,3,34-37 in which inhibition of PD- 
L1 and PD- 1 interaction with the anti- PD- 1 mAb resulted in 
the significant clinical response in the early phase clinical 
trial for advanced ESCC. EMT conversion of tumor cells 
is known to be one of the major steps for metastasis, and 
it has been reported that PD- L1 expression may be partially 
regulated by EMT- related gene.24,33,38 Therefore, we were 
interested in investigating the correlation between EMT sta-
tus and PD- L1 expression in ESCC. In the present study for 
ESCC, we showed a significant positive correlation between 
EMT status and PD- L1 expression in ESCC cell lines and 
clinical samples.
It has been reported that the upregulation of PD- L1 
on tumor cells can be mediated by several factors includ-
ing oncogenic pathway, epigenetic factors, and acquired 
immune response such as IFN- γ.18-23,39 EMT- inducing 
T A B L E  1  Patient and tumor characteristics






























Not poor 120 16
Poor 57 5
*7th edition of the UICC TNM classification of malignant tumors (ESCC).
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transcriptional factors are Snail 1/2, Twist, and ZEB- 1/2, 
which are controlled by several signaling pathways. Among 
these signaling pathways of EMT, the most prominent path-
way was reported to be TGF- β signaling pathway, which 
inhibited GSK- 3β that was located at the end of PI3K- 
Akt pathway. The inhibition of GSK- 3β can induce the 
upregulation of Snail, and subsequently, E- cadherin ex-
pression was downregulated, leading to mesenchymal phe-
notype.28,40-42 In the present study, we used SB- 415286 for 
EMT conversion in ESCC and our results clearly showed 
that GSK- 3β inhibition induced EMT conversion with up-
regulation of Snail and ZEB- 1, leading to phenotypic al-
teration with downregulated E- cadherin and upregulated 
vimentin in ESCC cell lines. As a result of EMT conver-
sion, the present study consistently showed the upregulation 
of PD- L1 on ESCC cells at both protein (total and surface) 
and mRNA levels in comparison to untreated original cell 
lines. Also, other regulatory factors for PD- L1 expression 
F I G U R E  4  Representative IHC for PD- L1, E- cadherin, and vimentin in esophageal squamous cell carcinoma (ESCC). PD- L1 was expressed 
in both tissue microarray samples (A) and formalin- fixed paraffin embedded tissue samples (B) of ESCC. A case with E- cadherin negative and 
vimentin positive was considered as epithelial- mesenchymal transition (EMT) (+), EMT status, which was expressing PD- L1 ((A) left, (B) left). On 
the other hand, a case with E- cadherin positive and vimentin negative was considered as EMT (−), epithelial phenotype, which was not expressing 
PD- L1 ((A) right, (B) right). Serial sections in the individual sample were used at a magnification of 10×, together with 40× magnification in small 
boxes showing the cell staining
F I G U R E  5  PD- L1 expression was increased in esophageal squamous cell carcinoma (ESCC) with epithelial- mesenchymal transition (EMT) 
status. The significant correlation between EMT status and PD- L1 expression in ESCC was seen in tissue microarray samples (A) (P = .0004) and 
formalin- fixed paraffin embedded tissue samples (B) (P = .0029). Uncertain cases, which were both E- cadherin and vimentin positive cases and 
both negative cases, were excluded from statistical analysis. Fischer’s exact test was used for the evaluation. **<.01, ***<.001
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including cell proliferative pathway, epigenetic factors, and 
acquired immune response such as IFN- γ18-23,39 are needed 
for the further investigation.
In order to further confirm the above findings, we per-
formed IHC with PD- L1, vimentin, and E- cadherin stain-
ing using TMA samples and FFPE tissue samples of ESCC. 
High E- cadherin score and low vimentin score were consid-
ered as epithelial type tumor, while low E- cadherin score 
and high vimentin score were considered as a mesenchymal 
type tumor in the present study. As a result, mesenchymal 
type tumors significantly expressed high PD- L1 expression 
in ESCC tumor samples in comparison with epithelial type. 
Collectively, our in vitro and in vivo study clearly confirmed 
that PD- L1 expression was upregulated in mesenchymal type 
tumors of ESCC.
As a significant novel finding in the present study, we 
showed that EMT- converted tumor cells have a capability 
to induce T- cell apoptosis to a greater extent in compari-
son with original epithelial type tumor cells. This observa-
tion implicated that although tumor cells could be primarily 
targeted by CTLs, EMT- converted tumor cells with upreg-
ulated PD- L1 expression make CTLs’ apoptosis through in-
teraction between PD- L1 and PD- 1.11,12,43 In this situation, 
EMT- converted tumor cells could escape from the immune 
system including CTLs- mediated lysis and reach the distant 
metastatic sites to establish new colonies. Although further 
study will be needed to resolve the relationship between cir-
culating tumor cells and cytotoxicity of CTLs, treatment with 
anti- PD- 1/anti- PD- L1 mAb could be a promising strategy for 
metastatic ESCC.
As described above, inhibition of GSK- 3 also induced 
upregulation of ZEB- 1, which was an EMT- inducing tran-
scriptional factor. ZEB- 1 suppressed microRNA- 200 that 
inhibited PD- L1 expression in microRNA- 200/ZEB- 1 
axis.24 In the present study, the upregulation of PD- L1 
and ZEB- 1 gene expression was simultaneously observed 
in tumor cell lines. According to the previous reports, the 
p53 was another possible pathway for PD- L1 regulation 
through microRNA- 34.21,44 Therefore, it is currently be-
lieved that there is a complicated situation between EMT 
conversion induced by GSK- 3 inhibitors and PD- L1 reg-
ulation, and it remains unknown which factors are located 
as upper- stream events. In the present study, although we 
showed the simultaneous downregulation of the epithelial 
marker E- cadherin and the upregulation of PD- L1 on the 
tumor cells, further studies are required to investigate the 
causative relationship between EMT conversion and PD- 
L1 expression.
In conclusion, our in vitro and in vivo study clearly con-
firmed that PD- L1 expression was upregulated in mesenchy-
mal type tumors of ESCC. These findings provide a strong 
rationale for clinical use of anti- PD- 1/anti- PD- L1 mAb for 
patients with advanced ESCC.
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